[{"address1": "10170 Church Ranch Way", "address2": "Suite 100", "city": "Westminster", "state": "CO", "zip": "80021", "country": "United States", "phone": "720 940 2200", "website": "https://www.arcabio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.", "fullTimeEmployees": 4, "companyOfficers": [{"maxAge": 1, "name": "Mr. Thomas A. Keuer", "age": 64, "title": "President, COO & Principal Executive Officer", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 400802, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. C. Jeffrey Dekker CPA", "age": 58, "title": "CFO, Treasurer & Company Secretary", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 323072, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://phx.corporate-ir.net/phoenix.zhtml?c=109749&p=irol-irhome", "maxAge": 86400, "priceHint": 4, "previousClose": 3.39, "open": 3.54, "dayLow": 3.4739, "dayHigh": 3.62, "regularMarketPreviousClose": 3.39, "regularMarketOpen": 3.54, "regularMarketDayLow": 3.4739, "regularMarketDayHigh": 3.62, "beta": 0.884, "forwardPE": -0.4056818, "volume": 39105, "regularMarketVolume": 39105, "averageVolume": 1496921, "averageVolume10days": 122140, "averageDailyVolume10Day": 122140, "bid": 3.52, "ask": 3.58, "bidSize": 500, "askSize": 100, "marketCap": 51790348, "fiftyTwoWeekLow": 1.56, "fiftyTwoWeekHigh": 4.49, "fiftyDayAverage": 2.954, "twoHundredDayAverage": 2.114, "currency": "USD", "enterpriseValue": 13324215, "floatShares": 4926626, "sharesOutstanding": 14507100, "sharesShort": 4096113, "sharesShortPriorMonth": 5662428, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.2824, "heldPercentInsiders": 0.0128999995, "heldPercentInstitutions": 0.75056, "shortRatio": 24.99, "shortPercentOfFloat": 0.395, "impliedSharesOutstanding": 14507100, "bookValue": 2.422, "priceToBook": 1.4739884, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -6002000, "trailingEps": -0.42, "forwardEps": -8.8, "lastSplitFactor": "1:18", "lastSplitDate": 1554336000, "enterpriseToEbitda": -1.672, "52WeekChange": 0.6298077, "SandP52WeekChange": 0.26137078, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "ABIO", "underlyingSymbol": "ABIO", "shortName": "ARCA biopharma, Inc.", "longName": "ARCA biopharma, Inc.", "firstTradeDateEpochUtc": 871047000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "aefe4f03-299b-3999-a469-92fced461200", "messageBoardId": "finmb_26198824", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.57, "recommendationKey": "none", "totalCash": 35903000, "totalCashPerShare": 2.475, "ebitda": -7968000, "totalDebt": 48000, "quickRatio": 22.709, "currentRatio": 23.194, "debtToEquity": 0.137, "returnOnAssets": -0.12667, "returnOnEquity": -0.15867, "freeCashflow": -3844750, "operatingCashflow": -4947000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-28"}]